FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 268 filers reported holding FATE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 1.51 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $1,580,000 | -1.2% | 27,000 | 0.0% | 0.05% | +4.2% |
Q3 2021 | $1,600,000 | -38.6% | 27,000 | -10.0% | 0.05% | -39.2% |
Q2 2021 | $2,604,000 | +5.3% | 30,000 | 0.0% | 0.08% | +1.3% |
Q1 2021 | $2,474,000 | -32.0% | 30,000 | -25.0% | 0.08% | -36.6% |
Q4 2020 | $3,637,000 | +51.7% | 40,000 | -33.3% | 0.12% | +25.5% |
Q3 2020 | $2,398,000 | +16.5% | 60,000 | 0.0% | 0.10% | +8.9% |
Q2 2020 | $2,059,000 | +54.5% | 60,000 | 0.0% | 0.09% | +23.3% |
Q1 2020 | $1,333,000 | -2.7% | 60,000 | -14.3% | 0.07% | +25.9% |
Q4 2019 | $1,370,000 | +26.0% | 70,000 | 0.0% | 0.06% | +23.4% |
Q3 2019 | $1,087,000 | -23.5% | 70,000 | 0.0% | 0.05% | -28.8% |
Q2 2019 | $1,421,000 | +15.5% | 70,000 | 0.0% | 0.07% | +15.8% |
Q1 2019 | $1,230,000 | +37.0% | 70,000 | 0.0% | 0.06% | +32.6% |
Q4 2018 | $898,000 | -21.2% | 70,000 | 0.0% | 0.04% | -17.3% |
Q3 2018 | $1,140,000 | +101.1% | 70,000 | +40.0% | 0.05% | +136.4% |
Q2 2018 | $567,000 | – | 50,000 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |